NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT03131648,Tralokinumab Monotherapy for Moderate to Severe Atopic Dermatitis - ECZTRA 1 (ECZema TRAlokinumab Trial no. 1),https://clinicaltrials.gov/study/NCT03131648,ECZTRA 1,COMPLETED,"Primary objective:

To evaluate the efficacy of tralokinumab compared with placebo in treating moderate to severe atopic dermatitis (AD).

Secondary objectives:

To evaluate the efficacy of tralokinumab on severity and extent of AD, itch, and health related quality of life compared with placebo.

Maintenance objective:

To evaluate maintenance of effect with continued tralokinumab dosing up to 52 weeks compared to placebo for subjects achieving clinical response at Week 16.",YES,Atopic Dermatitis,DRUG: Tralokinumab|DRUG: Placebo,"Subjects With Investigator's Global Assessment (IGA) Score of 0 (Clear) or 1 (Almost Clear) at Week 16, The IGA is an instrument used in clinical trials to rate the severity of the subject's global AD and is based on a 5-point scale ranging from 0 (clear) to 4 (severe)., At Week 16|Subjects Achieving at Least 75% Reduction in Eczema Area and Severity Index [EASI] at Week 16, The EASI is a validated measure used in clinical practice and clinical trials to assess the severity and extent of AD. The EASI is a composite index with scores ranging from 0 to 72, with higher values indicating more severe and/or more extensive condition., At Week 16","Reduction of Worst Daily Pruritus Numeric Rating Scale (Weekly Average) of at Least 4 From Baseline to Week 16., Subjects will assess their worst itch severity over the past 24 hours using an 11 point NRS ('Worst Daily Pruritus NRS') with 0 indicating 'no itch' and 10 indicating 'worst itch imaginable'., Week 0 to Week 16|Change in Scoring Atopic Dermatitis (SCORAD) From Baseline to Week 16, The SCORAD is a validated tool to evaluate the extent and severity of atopic dermatitis lesions, along with subjective symptoms. The score ranges from 0 to 103, with higher values indicating a more extensive and/or severe condition., Week 0 to Week 16|Change in Dermatology Life Quality Index (DLQI) Score From Baseline to Week 16, The Dermatology Life Quality Index (DLQI) is a validated questionnaire with content specific to those with dermatology conditions. It consists of 10 items addressing the subject's perception of the impact of their skin disease on different aspects of their quality of life (QoL) over the last week such as dermatology-related symptoms and feelings, daily activities, leisure, work or school, personal relationships, and the treatment. Each item is scored on a 4 point Likert scale (0 = not at all ⁄not relevant; 1 = a little; 2 = a lot; 3 = very much). The total score is the sum of the 10 items (0 to 30); a high score is indicative of a poor QoL., Week 0 to Week 16|Subjects With Investigator's Global Assessment (IGA) Score of 0 (Clear) or 1 (Almost Clear) at Week 52 Among Subjects With IGA of 0/1 at Week 16, The IGA is an instrument used in clinical trials to rate the severity of the subject's global AD and is based on a 5-point scale ranging from 0 (clear) to 4 (severe)., At Week 52|Subjects With at Least 75% Reduction in Eczema Area and Severity Index [EASI] at Week 52 Among Subjects With EASI75 at Week 16, The EASI is a validated measure used in clinical practice and clinical trials to assess the severity and extent of AD. The EASI is a composite index with scores ranging from 0 to 72, with higher values indicating more severe and/or more extensive condition., At Week 52|Safety and Tolerability: Adverse Event (AE) /Serious Adverse Event (SAE) Frequency, Overall summary of AEs and SAEs during the Initial treatment period is presented. For list of AEs and SAEs by MedDRA system organ class (SOC) and preferred term (PT) during the entire trial period (including safety follow-up), see Adverse Events Overview section., Week 0 to Week 16|Frequency of Anti-drug Antibodies, Anti-tralokinumab antibody levels were analysed using a validated bioanalytical method., Week 0 to Week 16|Subjects Achieving at Least 50% Reduction in Eczema Area and Severity Index [EASI] at Week 16, The EASI is a validated measure used in clinical practice and clinical trials to assess the severity and extent of AD. The EASI is a composite index with scores ranging from 0 to 72, with higher values indicating more severe and/or more extensive condition., At Week 16|Subjects Achieving at Least 90% Reduction in Eczema Area and Severity Index [EASI] at Week 16, The EASI is a validated measure used in clinical practice and clinical trials to assess the severity and extent of AD. The EASI is a composite index with scores ranging from 0 to 72, with higher values indicating more severe and/or more extensive condition., At Week 16|Change From Baseline to Week 16 in Eczema Area and Severity Index [EASI] Score, The EASI is a validated measure used in clinical practice and clinical trials to assess the severity and extent of AD. The EASI is a composite index with scores ranging from 0 to 72, with higher values indicating more severe and/or more extensive condition., Week 0 to Week 16|Subjects Achieving at Least 75% Reduction in Scoring Atopic Dermatitis (SCORAD) at Week 16, The SCORAD is a validated tool to evaluate the extent and severity of atopic dermatitis lesions, along with subjective symptoms. The score ranges from 0 to 103, with a higher values indicating a more extensive and/or severe condition., At Week 16|Subjects Achieving at Least 50% Reduction in Scoring Atopic Dermatitis (SCORAD) at Week 16, The SCORAD is a validated tool to evaluate the extent and severity of atopic dermatitis lesions, along with subjective symptoms. The score ranges from 0 to 103, with higher values indicating a more extensive and/or severe condition., At Week 16|Change From Baseline to Week 16 in Worst Daily Pruritus NRS (Weekly Average), Subjects will assess their worst itch severity over the past 24 hours using an 11 point NRS ('Worst Daily Pruritus NRS') with 0 indicating 'no itch' and 10 indicating 'worst itch imaginable', Week 0 to Week 16|Reduction of Worst Daily Pruritus NRS (Weekly Average) ≥3 From Baseline to Week 16, Subjects will assess their worst itch severity over the past 24 hours using an 11 point NRS ('Worst Daily Pruritus NRS') with 0 indicating 'no itch' and 10 indicating 'worst itch imaginable'., Week 0 to Week 16|Reduction From Baseline to Week 16 of Dermatology Life Quality Index (DLQI) of ≥4 Points Among Subjects With Baseline DLQI ≥4, The DLQI is a validated questionnaire with content specific to those with dermatology conditions. It consists of 10 items addressing the subject's perception of the impact of their skin disease on different aspects of their QoL over the last week such as dermatology related symptoms and feelings, daily activities, leisure, work or school, personal relationships, and the treatment. Each item is scored on a 4 point Likert scale (0 = not at all/not relevant; 1 = a little; 2 = a lot; 3 = very much). The total score is the sum of the 10 items (0 to 30); a high score is indicative of a poor QoL., Week 0 to Week 16",,LEO Pharma,,ALL,"ADULT, OLDER_ADULT",PHASE3,802,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",LP0162-1325|2016-004200-65,2017-05-30,2018-08-07,2019-10-10,2017-04-27,2020-09-15,2023-02-23,"Clinical Research Center of Alabama, Birmingham, Alabama, 35209, United States|Tien Q. Nguyen, MD, Inc., Fountain Valley, California, 92708, United States|Dermatology Research Associates, Los Angeles, California, 90045, United States|Quest Dermatology Research, Northridge, California, 91324, United States|Dermatology Specialists, Inc., Oceanside, California, 92056, United States|Center for Dermatology and Laser Surgery, Sacramento, California, 95819, United States|University Clinical Trials, Inc., San Diego, California, 92123, United States|The GWU Medical Faculty Associates, Washington, District of Columbia, 20037, United States|Skin Care Research, Inc., Boca Raton, Florida, 33486, United States|Park Avenue Dermatology, Orange Park, Florida, 32073, United States|Forward Clinical Trials, Tampa, Florida, 33624, United States|Research Institute of the Southeast, LLC, West Palm Beach, Florida, 33401, United States|ACRC Dermatology, West Palm Beach, Florida, 33406, United States|Georgia Pollens Clinical Research Centers, Inc., Albany, Georgia, 31707, United States|Allergy Center at Brookstone Research, Columbus, Georgia, 31904, United States|Dermatologic Surgery Specialists, Macon, Georgia, 31217, United States|Meridian Clinical Research, Savannah, Georgia, 31406, United States|Altman Dermatology Associates, Arlington Heights, Illinois, 60005, United States|PMG Research of Christie Clinic, Chicago, Illinois, 61820, United States|Deaconess Clinic, Evansville, Indiana, 47713, United States|Skin Sciences, PLLC, Louisville, Kentucky, 40217, United States|Clinical Trials of SWLA, LLC, Lake Charles, Louisiana, 70601, United States|DermAssociates, PC, Rockville, Maryland, 20850, United States|Clarkston Skin Research, Clarkston, Michigan, 48346, United States|Derm Center, Troy, Michigan, 48084, United States|MediSearch LLC, Saint Joseph, Missouri, 64506, United States|JDR Dermatology Research, Las Vegas, Nevada, 89148, United States|University at Buffalo Department of Dermatology, Buffalo, New York, 14203, United States|Weil Cornell Medicine, New York, New York, 10021, United States|Juva Skin & Laser Center, New York, New York, 10022, United States|Deramatology Consulting Services, PLLC, High Point, North Carolina, 27262, United States|Dermatologists of Greater Columbus, Bexley, Ohio, 43209, United States|University Hospitals Cleveland Medical Center, Cleveland, Ohio, 44106, United States|Oregon Medical Research Center, Portland, Oregon, 97223, United States|Oregon Health & Sciences University, Portland, Oregon, 97239, United States|UPMC Department of Dermatology, Pittsburgh, Pennsylvania, 15213, United States|Austin Dermatology Associates, Austin, Texas, 78705, United States|Tekton Research, Austin, Texas, 78745, United States|Dermtology Treatment and Research Center, Dallas, Texas, 75230, United States|Houston Skin Associates, Houston, Texas, 77004, United States|Center for Clinical Studies, Webster, Texas, 77958, United States|Virginia Clinical Research, Norfolk, Virginia, 23502, United States|Dermatology Associates of Seattle, Seattle, Washington, 98101, United States|West Virginia Research Institute, Morgantown, West Virginia, 26505, United States|Centre Hospitalier de Valence, Valence, Drôme, France|Hôpital St ANDRE, CHU de BORDEAUX, Service de Dermatologie, Bordeaux, France|CHRU de Brest - Hôpital Morvan, Service de Dermatologie, Brest Cedex, France|CHU de Dijon, Service de Dermatologie, Dijon, France|Hôpital Saint vincent de paul, Clinique de Dermatologie, Lille Cedex, France|Hôpital Claude Huriez-CHRU, Service de dermatologie, Lille, France|Cabinet Médical, Le Bateau Blanc-Immeuble A, Martigues, France|GHRMSA, Service de Dermatologie, Mulhouse, 68100, France|Centre Hospitalier Universitaire, Clinique dermatologique 7 eme nord, Nantes, France|Hôpital de l'Archet II, Service de Dermatologie- Vénérologie, Nice, France|Hôpital Robert Debré, Service de Dermatologie, Reims, France|Hôpital Charles Nicolle, Clinique Dermatologique, Rouen, France|C.H.U. de Saint-Etienne - Hôpital Nord, Service de dermatologie, Saint-Etienne Cedex 2, France|CHU de Toulouse Hôpital Larrey, Service de Dermatologie, Toulouse, France|Derma-Study-Center Friedrichshafen GmbH, Friedrichshafen, Baden-Württemberg, Germany|Klinikum Augsburg, Klinik für Dermatologie und Allergologie, Augsburg, Bavaria, Germany|Universitätsklinikum Erlangen, Hautklinik, Erlangen, Bavaria, Germany|LMU München, Klinik und Poliklinik für Dermatologie und Allergologie, München, Bavaria, Germany|Facharztpraxis für Dermatologie, Allergologie, Venerologie und Umweltmedizin, Mahlow, Brandenburg, Germany|Klinikum Darmstadt GmbH, Hautklinik, Darmstadt, Hessia, Germany|Hautärzte Zentrum Hannover, Hannöver, Lower Saxony, 30159, Germany|Medizinische Hochschule Hannover, Klinik für Dermatologie, Allergologie und Venerologie, Hannöver, Lower Saxony, Germany|KliFOs - Klinische Forschung Osnabrück, Osnabrück, Lower Saxony, Germany|Klinikum Bielefeld Rosenhöhe, Hautklinik, Bielefeld, NRW, Germany|Niesmann, Hautzentrum im Jahrhunderthaus, Bochum, NRW, Germany|Universitätsklinikum Bonn, Klinik und Poliklinik für Dermatologie und Allergologie, Bonn, NRW, Germany|Hautzentrum Dülmen, Dülmen, NRW, Germany|Universitätsklinikum Essen (AöR), Klinik für Dermatologie, Venerologie und Allergologie, Essen, NRW, Germany|Universitätsklinikum Münster Klinik und Poliklinik für Hautkrankheiten Münster, Zentrale Studienkoordination für innovative Dermatologie, Münster, NRW, Germany|Universitätsklinikum Halle (Saale), Universitätsklinik und Poliklinik für Dermatologie und Venerologie, Halle (Saale), Saxony-Anhalt, Germany|Universitätsklinikum Carl Gustav Carus, Klinik und Poliklinik für Dermatologie, Dresden, Saxony, Germany|Universitätsklinikum Leipzig, Klinik und Poliklinik für Dermatologie, Venerologie und Allergologie, Leipzig, Saxony, Germany|SRH Wald-Klinikum Gera, Klinik für klinische Studien, Gera, Thuringia, Germany|Charité - Universitätsmedizin Berlin, Klinik für Dermatologie, Allergologie und Venerologie, Berlin, Germany|CMB Collegium Medicum Berlin GmbH, Berlin, Germany|SCIderm GmbH, Hamburg, Germany|Meiwa Hospital, Hyōgo, Nishinomiya, 663-8186, Japan|Hyogo College Of Medicine Hospital, Hyōgo, Nishinomiya, 663-8501, Japan|KUME Clinic, Sakai City, Osaka, 593-8324, Japan|NTT Medical Center Tokyo, Tokyo, Shinagawa, 141-8625, Japan|Asahikawa City Hospital, Asahikawa, 070-8610, Japan|JR Sapporo Hospital, Chūō, 060-0033, Japan|Medical Corporation Kojinkai, Chūō, 060-0063, Japan|Fukuoka University Hospital, Fukuoka, 814-0180, Japan|Kurume University Hospital, Fukuoka, 830-0011, Japan|Fukushima Medical University Hospital, Fukushima, 960-1295, Japan|Gifu University Hospital, Gifu-shi, 315-0974, Japan|Osaka Habikono Medical Center, Habikino, 583-8588, Japan|Hamamatsu University hospital, Hamamatsu, 431-3192, Japan|Ichinomiya Municipal Hospital, Ichinomiya, 491-8558, Japan|Kagoshima University Hospital, Kagoshima, 890-8520, Japan|Kyoto Prefectural Hospital, Kyoto, 602-8566, Japan|Iwate Prefectural Central Hospital, Morioka, 020-0066, Japan|Chukyo Hospital, Nagoya, 457-8510, Japan|Takagi Dermatological Clinic, Obihiro, Japan|Jichi Medical University Hospital, Tochigi, 329-0498, Japan|Tokyo Teishin Hospital, Tokyo, 102-8798, Japan|The Jikei University Hospital, Tokyo, 105-8471, Japan|Nippon Medical School Hospital, Tokyo, 113-8603, Japan|The Fraternity Memorial Hospital, Tokyo, 130-8587, Japan|Tokyo Medical University Hospital, Tokyo, 160-0023, Japan|Ogikubo Hospital, Tokyo, 167-0035, Japan|Shirasaki Dermatology Clinic, Tōyama, 933-0871, Japan|Gokeikai Osaka Kaisei Hospital, Ōsaka, 532-0003, Japan|Osaka Hospital, Ōsaka, 553-0003, Japan|Hospital Reina Sofía, Servicio Dermatología, Córdoba, Andalucía, Spain|Hospital Virgen de la Macarena, Servicio Dermatología, Sevilla, Andalucía, Spain|Hospital Germans Trias i Pujol, Servicio Dermatología, Badalona, Catalunya, Spain|Hospital Clinic de Barcelona, Dermatology Department, Barcelona, Catalunya, Spain|Hospital de la Santa Creu i Sant Pau, Servicio Dermatología, Barcelona, Catalunya, Spain|Hospital del Mar, Servicio Dermatología, Barcelona, Catalunya, Spain|Clínica Universitaria de Navarra, Servicio Dermatología, Pamplona, Navarra, Spain|Hospital de Basurto, Servicio Dermatología, Bilbao, País Vasco, Spain|Hospital de Cruces, Servicio Dermatología, Bilbao, País Vasco, Spain|Hospital de Fuenlabrada, Servicio Dermatología, Madrid, Spain|Hospital Infanta Leonor, Servicio Dermatología, Madrid, Spain|Hospital Universitario de la Princesa, Servicio Dermatología, Madrid, Spain|Hospital Universitario La Paz, Servicio Dermatología, Madrid, Spain|Hospital Universitario y Politécnico La Fe, Servicio Dermatología, Valencia, Spain","Study Protocol, https://storage.googleapis.com/ctgov2-large-docs/48/NCT03131648/Prot_000.pdf|Statistical Analysis Plan, https://storage.googleapis.com/ctgov2-large-docs/48/NCT03131648/SAP_001.pdf"
